CommercialPrior AuthMedium impact
08.01.69d, Atezolizumab (Tecentriq®) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza TM)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2025
We identified it
Jun 19, 2026
Summary
Insurance company updated medical necessity criteria for Atezolizumab (Tecentriq) and Atezolizumab with Hyaluronidase-tqjs (Tecentriq Hybreza) effective January 1, 2025. This change affects prior authorization and coverage requirements for these cancer immunotherapy drugs.
Action Required
Immediately: Review updated medical necessity criteria for Tecentriq and Tecentriq Hybreza prior authorizations. Billing team and providers must ensure all future requests for these cancer immunotherapy drugs meet the new criteria effective January 1, 2025. Update prior authorization checklists and provider documentation requirements to align with new policy.